ZINFORO® Efficacy

Prescribing information is available at the bottom of this page.

ZINFORO® High clinical cure rate and evidence of rapid response in CAP

In Phase III trials, overall clinical cure rates were similar between ZINFORO® and ceftriaxone:2
  • 84.3% vs 77.7% (CE population)
  • 82.6% vs 76.6% (MITTE population)
70% of ZINFORO®-treated patients achieved clinical stability and improvement of symptoms by Day 4*†3
 
FOCUS 1 and 2: Clinical response rates at Day 4*†3

 

Consistently high early clinical response rates at Day 4, including for Streptococcus pneumoniae infections3

Footnotes: *ZINFORO® may be associated with early clinical response, based on clinical stability and symptom improvement criteria. Early clinical response does not predict final clinical outcome for ZINFORO®.3
Shown not to be statistically significant.3
Abbreviations: CAP, community-acquired pneumonia; CE, clinically evaluable; FOCUS, CeFtarOline Community-acquired pneumonia trial vs ceftriaxone in hospitalised patients; MITTE, modified intent-to-treat efficacy.
References:1. ZINFORO®. Summary of Product Characteristics; 2. File TM, et al. Clin Infect Dis 2010;51:1395–405; 3. Eckburg P, et al. Infect Dis Clin Pract 2012;20:254–60.

Be confident with ZINFORO® in challenging clinical scenarios with CAP

ZINFORO® delivers high cure rates in patients with severe disease, risk factors for difficult-to-treat infections and comorbidities2

 

ZINFORO® efficacy confirmed in CAP patients in a real-world setting

Clinical success in selected subgroups of the CAPTURE study‡3,4

High rates of overall clinical success observed across various real-world patient subgroups‡3,4

Footnotes: *CrCI 31–50 mL/min.2
†Bacteraemia was present in 4% of patients when baseline medical characteristics were assessed.2
‡CAPTURE was a retrospective cohort study relating to current treatment practice in the US. In CAPTURE, 'clinical success' was defined as clinical cure with no further need for antibiotic therapy or clinical improvement with switch to oral agents at end of ZINFORO® treatment. As CAPTURE is a retrospective chart review study, it has the limitations inherent to this study design.3,4
Abbreviations: CAP, community-acquired pneumonia; CAPTURE, Clinical Assessment Program and TEFLARO Utilization Registry; CrCl, creatinine clearance; PORT, Pneumonia Patient Outcomes Research Team.
References: 1. ZINFORO®. Summary of Product Characteristics; 2. File TM, et al. Clin Infect Dis 2010;51:1395–405; 3. Udeani G, et al. Hosp Prac 2014;42:109–15; 4. Maggiore C, et al. Expert Rev Clin Pharmacol 2015;8:141–53.

ZINFORO® High clinical cure rate and evidence of rapid response  with cSSTI

In Phase III trials, overall clinical cure rates were similar between ZINFORO® and vancomycin + aztreonam:*2

  • 91.6% vs 92.7% (CE population)

  • 85.9% vs 85.5% (MITT population)

74% of ZINFORO®-treated patients achieved clinical stability and improvement of symptoms by Day 3†3

 

 

ZINFORO® was associated with a trend towards early clinical response when compared to vancomycin + aztreonam at Day 33

 

Footnotes: *There is no experience with ZINFORO® in the treatment of cSSTI in the following patient groups: The immunocompromised; patients with severe sepsis/septic shock; necrotising fasciitis; perirectal abscess; and patients with third-degree and extensive burns. There is limited experience in treating patients with diabetic foot infections. Caution is advised when treating such patients.1
†ZINFORO® was associated with a non-statistical significant early clinical response defined by cessation of lesion spread and absence of fever.3
Abbreviations: CE, clinically evaluable; cSSTI, complicated skin and soft tissue infections; MITT, modified intent-to-treat; MRSA, methicillin-resistant Staphylococcus aureus.
References: 1. ZINFORO®. Summary of Product Characteristics; 2. Corey G, et al. Clin Infect Dis 2010;51:641–50; 3. Friedland D, et al. Antimicrob Agents Chemother 2012;56;2231–6.

Be confident with ZINFORO® in challenging clinical scenarios with cSSTI

ZINFORO® delivers high cure rates in patients with severe disease and comorbidities*2

Clinical response rates at TOC by subgroup (CANVAS 1 & 2)

 

 

ZINFORO® efficacy confirmed in cSSTI patients in a real-world setting

Clinical success in selected subgroups of the CAPTURE study‡3–5

Clinical success rate of 85% with ZINFORO® in cSSTI in real-world patients4

 
Footnotes: *There is no experience with ZINFORO® in the treatment of cSSTIin the following patient groups: The immunocompromised; patients with severe sepsis/septic shock; necrotising fasciitis; perirectal abscess; and patients with third-degree and extensive burns. There is limited experience in treating patients with diabetic foot infections. Caution is advised when treating such patients.1
Bacteraemia was present in 4% of patients when baseline medical characteristics were assessed.2
CAPTURE was a retrospective cohort study relating to current treatment practice in the US. In CAPTURE, 'clinical success' was defined as clinical cure with no further need for antibiotic therapy or clinical improvement with switch to oral agents at end of ZINFORO® treatment. As CAPTURE is a retrospective chart review study, it has the limitations inherent to this study design.3–5
§ZINFORO® is suitable for patients with a range of BMIs, and doesn't need to be dosed on a weight basis.5
Normal/mild renal insufficiency, or moderate or severe renal insufficiency. Overall clinical success rates were 88–91%.3
Abbreviations: BMI, body mass index; CANVAS, CeftAroliNe fosamil vs Vancomycin in Skin and skin structure infection; CAPTURE, Clinical Assessment Program and TEFLARO Utilization Registry; cSSTI, complicated skin and soft tissue infections; MRSA, methicillin-resistant Staphylococcus aureus; TOC, test-of-cure.
References: 1. ZINFORO®. Summary of Product Characteristics; 2. Corey G, et al. Clin Infect Dis 2010;51:641–50; 3. Maggiore C, et al. Expert Rev Clin Pharmacol 2015;8:141–53; 4. Santos PD, et al. J Chemother 2013;25:341–6; 5. Evans JD, et al. Postgrad Med 2014;126:128–34.

ZINFORO® 600 mg powder for concentrate for solution for infusion – SPC
Legal category: POM.   Basic NHS cost: 10 vial pack £375.00.

Vancomycin – SPC
Legal Category: POM       Basic NHS Cost: 500 mg 10 vial pack £8.50, 1000 mg 10 vial pack £17.25

PP-ZFO-GBR-0028

Date of Preparation: June 2018